WeVote
Log In

Bill

Bill

S 3351

Adds tianeptine sodium to the list of Schedule II of controlled substances

2025 Regular Session Introduced by James Skoufis

Bill S 3351 classifies tianeptine sodium as a Schedule II controlled substance, imposing stricter regulations on prescriptions to curb potential abuse and dependency.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · S 3351

Summary of Bill S 3351

Bill Overview

  • Bill Number: S 3351
  • Title: Adds tianeptine sodium to the list of Schedule II controlled substances
  • Status: Referred to Health
  • Introduced On: January 27, 2025

Purpose and Intent

The primary purpose of Bill S 3351 is to classify tianeptine sodium as a Schedule II controlled substance. This classification aims to regulate the use, distribution, and prescription of tianeptine sodium due to concerns regarding its potential for abuse and dependency.

Key Provisions

  • Inclusion in Schedule II: The bill proposes that tianeptine sodium be added to the list of substances classified as Schedule II under the Controlled Substances Act. This classification indicates that while the substance has accepted medical uses, it also has a high potential for abuse, which may lead to severe psychological or physical dependence.

  • Regulatory Framework: By categorizing tianeptine sodium as a Schedule II substance, the bill would impose stricter regulations on its prescribing and dispensing. This includes:

    • Prescription Requirements: Tianeptine sodium would require a prescription from a licensed healthcare provider.
    • Record Keeping: Pharmacists and healthcare providers would need to maintain detailed records of prescriptions and dispensed amounts.
    • Monitoring: Increased monitoring of prescriptions to prevent misuse and ensure compliance with regulations.

Affected Parties

  • Healthcare Providers: Physicians and other licensed prescribers will need to adapt to the new regulations regarding prescribing tianeptine sodium.
  • Pharmacies: Pharmacies will be required to implement stricter inventory and record-keeping practices for tianeptine sodium.
  • Patients: Individuals who are currently prescribed tianeptine sodium may face changes in access and availability due to the new scheduling.

Procedural Aspects

  • Current Status: As of January 27, 2025, the bill has been referred to the Health Committee for further consideration.
  • Related Legislation: This bill is related to several prior-session bills, including:
    • S 8023
    • S 1776
    • S 1720
    • A 7501 (companion bill)

These related bills may provide context or additional legislative efforts surrounding the regulation of tianeptine sodium and similar substances.

Conclusion

Bill S 3351 seeks to address public health concerns regarding tianeptine sodium by regulating its use as a controlled substance. If passed, it will impact healthcare providers, pharmacies, and patients, necessitating adjustments to prescribing practices and access to the substance. The bill is currently under review by the Health Committee, and its progress will be closely monitored by stakeholders in the healthcare community.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.